Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Liminatus Pharma ( (LIMN) ) just unveiled an update.
On May 29, 2025, Liminatus Pharma, Inc. received a notice from the Nasdaq Listing Qualifications Department indicating non-compliance with Nasdaq Listing Rule 5250(c)(1) due to a delay in filing its Quarterly Report for the period ended March 31, 2025. The company filed the report on June 2, 2025, and by June 3, 2025, it received confirmation of regained compliance, closing the matter.
More about Liminatus Pharma
Average Trading Volume: 34,809
Technical Sentiment Signal: Sell
Current Market Cap: $38.13M
Learn more about LIMN stock on TipRanks’ Stock Analysis page.